Insulet (PODD) Competitors $323.07 +1.80 (+0.56%) Closing price 04:00 PM EasternExtended Trading$323.08 +0.00 (+0.00%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PODD vs. BDX, IDXX, EW, RMD, DXCM, STE, HOLX, BAX, GMED, and MASIShould you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), Edwards Lifesciences (EW), ResMed (RMD), DexCom (DXCM), STERIS (STE), Hologic (HOLX), Baxter International (BAX), Globus Medical (GMED), and Masimo (MASI). These companies are all part of the "health care equipment" industry. Insulet vs. Its Competitors Becton, Dickinson and Company IDEXX Laboratories Edwards Lifesciences ResMed DexCom STERIS Hologic Baxter International Globus Medical Masimo Insulet (NASDAQ:PODD) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability. Is PODD or BDX more profitable? Insulet has a net margin of 10.01% compared to Becton, Dickinson and Company's net margin of 7.51%. Insulet's return on equity of 23.78% beat Becton, Dickinson and Company's return on equity.Company Net Margins Return on Equity Return on Assets Insulet10.01% 23.78% 9.30% Becton, Dickinson and Company 7.51%16.23%7.46% Does the media favor PODD or BDX? In the previous week, Becton, Dickinson and Company had 18 more articles in the media than Insulet. MarketBeat recorded 35 mentions for Becton, Dickinson and Company and 17 mentions for Insulet. Becton, Dickinson and Company's average media sentiment score of 1.31 beat Insulet's score of 1.26 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Becton, Dickinson and Company 25 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, PODD or BDX? Insulet has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Do analysts prefer PODD or BDX? Insulet currently has a consensus price target of $330.71, indicating a potential upside of 2.47%. Becton, Dickinson and Company has a consensus price target of $211.44, indicating a potential upside of 8.33%. Given Becton, Dickinson and Company's higher probable upside, analysts plainly believe Becton, Dickinson and Company is more favorable than Insulet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insulet 0 Sell rating(s) 2 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.89Becton, Dickinson and Company 0 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.36 Which has better earnings and valuation, PODD or BDX? Becton, Dickinson and Company has higher revenue and earnings than Insulet. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsulet$2.07B10.97$418.30M$3.2998.09Becton, Dickinson and Company$20.18B2.77$1.71B$5.5635.10 Do institutionals & insiders believe in PODD or BDX? 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 0.4% of Insulet shares are held by insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryInsulet beats Becton, Dickinson and Company on 9 of the 16 factors compared between the two stocks. Get Insulet News Delivered to You Automatically Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PODD vs. The Competition Export to ExcelMetricInsuletMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.73B$10.48B$5.71B$9.79BDividend YieldN/A1.90%3.77%4.10%P/E Ratio98.1420.6830.9125.28Price / Sales10.9733.37404.2188.50Price / Cash72.4224.9525.2228.45Price / Book18.693.469.536.01Net Income$418.30M$209.94M$3.26B$265.34M7 Day Performance5.87%4.20%4.66%2.89%1 Month Performance13.54%12.97%5.35%1.61%1 Year Performance66.77%-8.68%32.14%25.61% Insulet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PODDInsulet4.2531 of 5 stars$323.07+0.6%$330.71+2.4%+66.0%$22.74B$2.07B98.203,900Positive NewsBDXBecton, Dickinson and Company4.6553 of 5 stars$192.53-0.5%$211.44+9.8%-17.1%$55.18B$21.39B34.6374,000Positive NewsIDXXIDEXX Laboratories4.3347 of 5 stars$652.11-0.9%$644.67-1.1%+32.2%$52.17B$4.04B54.3011,000Positive NewsAnalyst ForecastAnalyst RevisionEWEdwards Lifesciences4.4735 of 5 stars$78.23-0.2%$85.90+9.8%+13.6%$45.93B$5.44B11.2615,800Positive NewsAnalyst RevisionRMDResMed4.6467 of 5 stars$284.33+0.2%$274.83-3.3%+25.1%$41.69B$5.15B29.909,980Positive NewsDXCMDexCom4.8313 of 5 stars$77.85-1.3%$99.89+28.3%+8.4%$30.53B$4.30B54.0610,300Positive NewsSTESTERIS4.5631 of 5 stars$241.66-0.5%$273.50+13.2%+5.7%$23.77B$5.57B37.0117,787Positive NewsHOLXHologic4.8645 of 5 stars$67.99-0.1%$77.83+14.5%-16.8%$15.12B$4.03B28.217,063Positive NewsAnalyst UpgradeBAXBaxter International4.9199 of 5 stars$23.47-0.9%$30.11+28.3%-33.0%$12.05B$10.89B-78.2338,000GMEDGlobus Medical4.9624 of 5 stars$59.46+1.4%$87.64+47.4%-13.2%$8.05B$2.52B22.875,300MASIMasimo4.4674 of 5 stars$147.37+1.8%$193.60+31.4%+24.7%$8.01B$2.15B-17.305,600 Related Companies and Tools Related Companies Becton, Dickinson and Company Alternatives IDEXX Laboratories Alternatives Edwards Lifesciences Alternatives ResMed Alternatives DexCom Alternatives STERIS Alternatives Hologic Alternatives Baxter International Alternatives Globus Medical Alternatives Masimo Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PODD) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access